PetMeds (PETS) Q1 2027 earnings review
Cash Crunch Forces Lifeline Sale as Revenue Slide Continues
PetMeds is in a race against its own balance sheet. Despite management claiming 'sequential quarterly stabilization,' revenue fell 19.9% YoY to $41.0 million, and Adjusted EBITDA losses widened to $3.4 million. The true alarm bell is liquidity: the company burned through 39% of its cash in a single quarter, dropping the balance to just $13.1 million. This forced a dilutive $37 million sale-leaseback of its headquarters just to keep the turnaround funded. While G&A cuts are executing well and a new SAP ERP system is live, the core business is still shrinking too fast to achieve profitability on its own cash generation.
🐂 Bull Case
CAC dropped 15% YoY, yielding 70,000 new customers despite a 30% reduction in total advertising spend. Management is buying traffic much more efficiently.
The enterprise-wide SAP ERP rollout is finished. The heavy lifting on infrastructure modernization is done, allowing full focus on sales execution.
🐻 Bear Case
An $8.3M quarterly cash burn left only $13.1M in the bank, necessitating a $37M property sale that will add lease liabilities to an already unprofitable business.
Adjusted EBITDA losses widened from $2.7M to $3.4M as supplier rebates shrank, proving that aggressive cost cutting isn't keeping pace with revenue decay.
⚖️ Verdict: 🔴
Bearish. The $37M sale-leaseback buys time, but with YoY revenue declines accelerating and EBITDA losses widening, the operational turnaround is not materializing fast enough to inspire confidence.
Key Themes
Cash Bleed and the Real Estate Lifeline
Accelerating. Operating cash burn of $7.7M decimated the balance sheet, dropping cash from $21.4M to $13.1M in three months. Management announced a $37M sale-leaseback of their HQ and distribution center to raise capital. While pitched as 'enhancing financial flexibility,' it is a survival mechanism. It trades a hard asset for cash while adding future lease liabilities to an already unprofitable business.
The 'Stabilization' Illusion
Accelerating. Management cited 'sequential quarterly stabilization,' but the data contradicts the optimism. YoY revenue decline actually accelerated from -15.6% in 26Q4 to -19.9% in 27Q1. Sequentially, sales still dropped from $42.8M to $41.0M. The core engine—prescription medication sales—remains in active contraction.
Margin Squeeze & Loss of Supplier Leverage
Decelerating. Gross margin compressed from 28.1% to 27.6%, driving Adjusted EBITDA losses wider. Management explicitly blamed 'lower manufacturer rebates.' This highlights a dangerous macro and competitive trend: as PetMeds loses market share to larger retail rivals, it loses volume-based pricing power and tier-rebates with pharmaceutical suppliers.
Marketing Efficiency Rebounding
Accelerating. In a rare bright spot, the marketing reset is showing traction. The company acquired 70,000 new customers while reducing its Customer Acquisition Cost (CAC) by 15% YoY. Advertising spend was slashed by 30% to $4.2M, proving they can buy traffic more efficiently than before.
SAP ERP Rollout Completes Foundational Rebuild
Stable. The enterprise-wide rollout of the SAP ERP system was completed this quarter. Paired with last quarter's fraud prevention and AI call center deployments, the company's long-standing excuse of 'legacy technology debt' is officially resolved. The modernized stack must now prove it can drive conversion and retention.
Freight Cost Optimizations
Accelerating. While gross margins were pressured by supplier rebates, management noted that this was partially offset by lower net freight costs per order. As shipping costs have historically crushed D2C margins, this operational efficiency shows the logistics and fulfillment side of the house is tightening up.
Other KPIs
Decelerating. A 13.5% YoY reduction, proving management is executing on its promise to right-size the cost structure after exiting underperforming vendor relationships. However, these cuts are merely offsetting top-line decay rather than creating operating leverage.
Reversing. Cash flow from operations was deeply negative at -$7.7M, compounded by -$0.6M in CapEx. This is the metric that triggered the $37M sale-leaseback, as the company could not sustain this burn rate against its previous $21.4M cash buffer.
Key Questions
Cash Runway Visibility
What is the expected monthly cash burn rate over the remainder of FY27, and does the $37M sale-leaseback provide enough runway to reach actual EBITDA profitability without further dilutive actions?
Supplier Rebate Dynamics
Manufacturer rebates declined as a percentage of sales. Is this a temporary timing issue, or a structural change in how manufacturers are treating volume-based tier pricing in the highly competitive pet pharmacy space?
New Customer Cohort Quality
You acquired 70,000 new customers at a 15% lower CAC, but overall prescription sales still declined. Are these new cohorts primarily buying lower-margin OTC products, and what is their early repeat purchase rate compared to legacy customers?